Compare ABEO & ALOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABEO | ALOV |
|---|---|---|
| Founded | 1974 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 399.5M | 374.4M |
| IPO Year | 2005 | 2025 |
| Metric | ABEO | ALOV |
|---|---|---|
| Price | $5.97 | $9.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 100.5K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $1,024.31 | N/A |
| Revenue Next Year | $145.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $4.00 | $9.83 |
| 52 Week High | $7.65 | $10.00 |
| Indicator | ABEO | ALOV |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 57.43 |
| Support Level | $5.83 | N/A |
| Resistance Level | $5.97 | N/A |
| Average True Range (ATR) | 0.21 | 0.01 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 34.68 | 80.00 |
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Aldabra 4 Liquidity Opportunity Vehicle Inc is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.